RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction

Cell Reports

Volumn 3, Issue 1, 2013, Pages 116-127

  Wilkinson, Adam C ^a   Ballabio, Erica ^a   Geng, Huimin ^b,c   North, Phillip ^a   Tapia, Marta ^a   Kerry, Jon ^a   Biswas, Debabrata ^d   Roeder, Robert G ^d   Allis, C David ^d   Melnick, Ari ^b   de Bruijn, Marella F T R ^a   Milne, Thomas A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF4 PROTEIN; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR FOXP2; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SOX4; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; COMPLEX FORMATION; CONTROLLED STUDY; EPIGENETICS; GENE ACTIVATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC LOCI; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN BINDING; PROTEIN STABILITY; TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84873133035     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.12.016     Document Type: Article

References (57)

1. Akalin A., Garrett-Bakelman F.E., Kormaksson M., Busuttil J., Zhang L., Khrebtukova I., Milne T.A., Huang Y., Biswas D., Hess J.L., et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 2012, 8:e1002781.
2. Bardini M., Spinelli R., Bungaro S., Mangano E., Corral L., Cifola I., Fazio G., Giordan M., Basso G., De Rossi G., et al. DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia 2010, 24:169-176.
3. Bardini M., Galbiati M., Lettieri A., Bungaro S., Gorletta T.A., Biondi A., Cazzaniga G. Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia 2011, 25:175-178.
4. Benedikt A., Baltruschat S., Scholz B., Bursen A., Arrey T.N., Meyer B., Varagnolo L., Müller A.M., Karas M., Dingermann T., Marschalek R. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 2011, 25:135-144.
5. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
6. Biswas D., Milne T.A., Basrur V., Kim J., Elenitoba-Johnson K.S., Allis C.D., Roeder R.G. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc. Natl. Acad. Sci. USA 2011, 108:15751-15756.
7. Blyth K., Cameron E.R., Neil J.C. The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 2005, 5:376-387.
8. Bursen A., Moritz S., Gaussmann A., Moritz S., Dingermann T., Marschalek R. Interaction of AF4 wild-type and AF4.MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?. Oncogene 2004, 23:6237-6249.
9. Bursen A., Schwabe K., Rüster B., Henschler R., Ruthardt M., Dingermann T., Marschalek R. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 2010, 115:3570-3579.
10. Chen W., Li Q., Hudson W.A., Kumar A., Kirchhof N., Kersey J.H. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006, 108:669-677.
11. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
12. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
13. Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., Allis C.D., Chait B.T., Hess J.L., Roeder R.G. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005, 121:873-885.
14. Drynan L.F., Pannell R., Forster A., Chan N.M., Cano F., Daser A., Rabbitts T.H. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J. 2005, 24:3136-3146.
15. Geng H., Brennan S., Milne T.A., Chen W.Y., Li Y., Hurtz C., Kweon S.M., Zickl L., Shojaee S., Neuberg D., et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012, 2:1004-1023.
16. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
17. Harvey R.C., Mullighan C.G., Wang X., Dobbin K.K., Davidson G.S., Bedrick E.J., Chen I.M., Atlas S.R., Kang H., Ar K., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116:4874-4884.
18. Hsieh J.J., Ernst P., Erdjument-Bromage H., Tempst P., Korsmeyer S.J. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol. Cell. Biol. 2003, 23:186-194.
19. Huang G., Zhang P., Hirai H., Elf S., Yan X., Chen Z., Koschmieder S., Okuno Y., Dayaram T., Growney J.D., et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat. Genet. 2008, 40:51-60.
20. Huang G., Zhao X., Wang L., Elf S., Xu H., Zhao X., Sashida G., Zhang Y., Liu Y., Lee J., et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 2011, 118:6544-6552.
21. Jude C.D., Climer L., Xu D., Artinger E., Fisher J.K., Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007, 1:324-337.
22. Kowarz E., Burmeister T., Lo Nigro L., Jansen M.W., Delabesse E., Klingebiel T., Dingermann T., Meyer C., Marschalek R. Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. Leukemia 2007, 21:1232-1238.
23. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
24. Kumar A.R., Yao Q., Li Q., Sam T.A., Kersey J.H. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL. Leuk. Res. 2011, 35:305-309.
25. Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
26. Mangan J.K., Speck N.A. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit. Rev. Oncog. 2011, 16:77-91.
27. Marschalek R. Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J. 2010, 277:1822-1831.
28. Marschalek R. It takes two-to-leukemia: about addictions and requirements. Leuk. Res. 2011, 35:424-425.
29. Marshall N.F., Price D.H. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol. Chem. 1995, 270:12335-12338.
30. McMahon K.A., Hiew S.Y., Hadjur S., Veiga-Fernandes H., Menzel U., Price A.J., Kioussis D., Williams O., Brady H.J. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 2007, 1:338-345.
31. Metzler M., Forster A., Pannell R., Arends M.J., Daser A., Lobato M.N., Rabbitts T.H. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006, 25:3093-3103.
32. Meyer C., Kowarz E., Hofmann J., Renneville A., Zuna J., Trka J., Ben Abdelali R., Macintyre E., De Braekeleer E., De Braekeleer M., et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23:1490-1499.
33. Mikhail F.M., Serry K.A., Hatem N., Mourad Z.I., Farawela H.M., El Kaffash D.M., Coignet L., Nucifora G. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia 2002, 16:658-668.
34. Milne T.A., Briggs S.D., Brock H.W., Martin M.E., Gibbs D., Allis C.D., Hess J.L. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 2002, 10:1107-1117.
35. Milne T.A., Martin M.E., Brock H.W., Slany R.K., Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005, 65:11367-11374.
36. Milne T.A., Zhao K., Hess J.L. Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol. Biol. 2009, 538:409-423.
37. Milne T.A., Kim J., Wang G.G., Stadler S.C., Basrur V., Whitcomb S.J., Wang Z., Ruthenburg A.J., Elenitoba-Johnson K.S., Roeder R.G., Allis C.D. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell 2010, 38:853-863.
38. Montero-Ruíz O., Alcántara-Ortigoza M.A., Betancourt M., Juárez-Velázquez R., González-Márquez H., Pérez-Vera P. Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia. Leuk. Res. 2012, 36:1105-1111.
39. Montes R., Ayllón V., Gutierrez-Aranda I., Prat I., Hernández-Lamas M.C., Ponce L., Bresolin S., Te Kronnie G., Greaves M., Bueno C., Menendez P. Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 2011, 117:4746-4758.
40. Mueller D., Bach C., Zeisig D., Garcia-Cuellar M.P., Monroe S., Sreekumar A., Zhou R., Nesvizhskii A., Chinnaiyan A., Hess J.L., Slany R.K. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007, 110:4445-4454.
41. Muntean A.G., Tan J., Sitwala K., Huang Y., Bronstein J., Connelly J.A., Basrur V., Elenitoba-Johnson K.S., Hess J.L. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010, 17:609-621.
42. Nakamura T., Mori T., Tada S., Krajewski W., Rozovskaia T., Wassell R., Dubois G., Mazo A., Croce C.M., Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 2002, 10:1119-1128.
43. Niini T., Vettenranta K., Hollmén J., Larramendy M.L., Aalto Y., Wikman H., Nagy B., Seppänen J.K., Ferrer Salvador A., Mannila H., et al. Expression of myeloid-specific genes in childhood acute lymphoblastic leukemia - a cDNA array study. Leukemia 2002, 16:2213-2221.
44. Nishimoto N., Arai S., Ichikawa M., Nakagawa M., Goyama S., Kumano K., Takahashi T., Kamikubo Y., Imai Y., Kurokawa M. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. Blood 2011, 118:2541-2550.
45. Nottingham W.T., Jarratt A., Burgess M., Speck C.L., Cheng J.F., Prabhakar S., Rubin E.M., Li P.S., Sloane-Stanley J., Kong-A-San J., de Bruijn M.F. Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer. Blood 2007, 110:4188-4197.
46. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
47. Pencovich N., Jaschek R., Tanay A., Groner Y. Dynamic combinatorial interactions of RUNX1 and cooperating partners regulates megakaryocytic differentiation in cell line models. Blood 2011, 117:e1-e14.
48. Ross M.E., Zhou X., Song G., Shurtleff S.A., Girtman K., Williams W.K., Liu H.C., Mahfouz R., Raimondi S.C., Lenny N., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102:2951-2959.
49. Stam R.W., Schneider P., Hagelstein J.A., van der Linden M.H., Stumpel D.J., de Menezes R.X., de Lorenzo P., Valsecchi M.G., Pieters R. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010, 115:2835-2844.
50. Thomas M., Gessner A., Vornlocher H.P., Hadwiger P., Greil J., Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005, 106:3559-3566.
51. Trentin L., Giordan M., Dingermann T., Basso G., Te Kronnie G., Marschalek R. Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur. J. Haematol. 2009, 83:406-419.
52. Xia Z.B., Popovic R., Chen J., Theisler C., Stuart T., Santillan D.A., Erfurth F., Diaz M.O., Zeleznik-Le N.J. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl. Acad. Sci. USA 2005, 102:14028-14033.
53. Yokoyama A., Kitabayashi I., Ayton P.M., Cleary M.L., Ohki M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 2002, 100:3710-3718.
54. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
55. Zeisig D.T., Bittner C.B., Zeisig B.B., García-Cuéllar M.P., Hess J.L., Slany R.K. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 2005, 24:5525-5532.
56. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., Easton J., Chen X., Wang J., Rusch M., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
57. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.